Acadia Pharmaceuticals (ACAD) Short-term Investments (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Short-term Investments of $569.2 million for Q1 2026, up 22.71% year-over-year from $463.9 million in Q1 2025, and down 11.33% quarter-over-quarter from $642.0 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Short-term Investments (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $569.2 million for Q1 2026.
- In Q1 2026, Short-term Investments rose 22.71% year-over-year to $569.2 million; the TTM figure through Mar 2026 stood at $569.2 million (up 22.71% YoY), while the FY2025 annual figure was $642.0 million, up 47.11% from the prior year.
- Short-term Investments for Q1 2026 stood at $569.2 million, down from $642.0 million in the prior quarter.
- The five-year high for Short-term Investments was $642.0 million in Q4 2025, with the low at $112.0 million in Q1 2023.
- The 5-year median for Short-term Investments is $302.0 million (2022), against an average of $365.1 million.
- The sharpest annual moves came in 2023 and 2024: Short-term Investments tumbled 53.55% in 2023, then surged 137.35% in 2024.
- Acadia Pharmaceuticals' Short-term Investments stood at $302.0 million in 2022, then retreated by 17.14% to $250.2 million in 2023, then soared by 74.42% to $436.4 million in 2024, then surged by 47.11% to $642.0 million in 2025, then slipped by 11.33% to $569.2 million in 2026.
- Business Quant data shows ACAD's Short-term Investments at $569.2 million in Q1 2026, $642.0 million in Q4 2025, and $589.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 571.49 Mn |
| Mar 31, 2026 | 569.25 Mn |
| Dec 31, 2025 | 641.99 Mn |
| Sep 30, 2025 | 589.02 Mn |
| Jun 30, 2025 | 508.36 Mn |
| Mar 31, 2025 | 463.88 Mn |
| Dec 31, 2024 | 436.40 Mn |
| Sep 30, 2024 | 410.18 Mn |
| Jun 30, 2024 | 323.81 Mn |
| Mar 31, 2024 | 265.78 Mn |
| Dec 31, 2023 | 250.21 Mn |
| Sep 30, 2023 | 247.73 Mn |
| Jun 30, 2023 | 267.44 Mn |
| Mar 31, 2023 | 111.98 Mn |
| Dec 31, 2022 | 301.98 Mn |
| Sep 30, 2022 | 281.74 Mn |
| Jun 30, 2022 | 296.52 Mn |
| Mar 31, 2022 | 241.06 Mn |
| Dec 31, 2021 | 373.27 Mn |
| Sep 30, 2021 | 445.65 Mn |